How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
longer and switched less often than matched patients on AUSTEDO XR over six months, based on 2,988 U.S. patients in an IQVIA LAAD retrospective analysis completed between 2022 and 2025. This early and sustained difference in treatment persistence, when combined with prior clinical outcomes data, may further reinforce INGREZZA's role as a first-line option in tardive dyskinesia treatment decisions. We'll now examine how higher real-world treatment persistence for INGREZZA may influence Neurocrine's investment narrative and long-term growth assumptions. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Neurocrine Biosciences Investment Narrative Recap To own Neurocrine, you need to believe that INGREZZA can remain the anchor franchise w
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences (NBIX) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [TheStreet.com]TheStreet.com
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial ResultsPR Newswire
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 4/15/26 - Form DEFA14A
- 4/15/26 - Form ARS
- 4/15/26 - Form DEF
- NBIX's page on the SEC website